Oct 27, 2024, 17:41
Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease
Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared on X:
“S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease to direct Therapy Duration (DRAMMATIC) – Amrita Krishnan, Hoering, Phari, Sexton, Robert Z. Orlowski.
ASH20 Abstract 1515
Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton, Robert Z. Orlowski
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 27, 2024, 17:41
Oct 27, 2024, 17:31
Oct 27, 2024, 17:16
Oct 27, 2024, 17:11
Oct 27, 2024, 17:07
Oct 27, 2024, 16:50
Oct 27, 2024, 16:43
Oct 27, 2024, 14:33
Oct 27, 2024, 14:23